AI Consensus Investment Thesis
Gilead Sciences (GILD) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
NEUTRAL
Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.
1-Year
BUY$159
+6.0%+8.7% incl. dividends5-Year
NEUTRAL$191
+27.1%+43.8% incl. dividendsLatest flagship insight
Biopharma Cash Engine Confronts Impending Regulatory Price Squeeze and Patent Cliffs
Sharp divergence defines the analytical outlook, contrasting transformative twice-yearly capsid prevention adoption against mandatory statutory Medicare pricing concessions. Entrenched virology cash generation comfortably absorbs recent multi-billion acquired research charges, yet looming exclusivity horizons and capital allocation discipline dictate whether long-term valuation multiples can expand sustainably.
This is the latest published deep-analysis batch. Audit published forecasts in full transparency
Elon Musk (Visionary), Michael Burry (Vulture), Warren Buffett (Value Purist), Superintelligence (Anthropologist), Universal Investor (Polymath), Sherlock Holmes (Whistleblower), Ray Dalio (Strategist), J.P. Morgan (Titan), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.
Gemini
Claude
ChatGPTExecutive Summary
Dotted terms open concise definitions. Browse technical terms
If you invested $10,000 in Gilead Sciences at the forecast anchor (2026-09-18): $14,379 in five years versus $13,892 for S&P 500 benchmark.
* Return is calculated incl. 2.5% net dividend yield for Gilead Sciences.
20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView tableClose table
Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.
Swipe the table horizontally to read every column.
| Quarter | Target (USD) | Quarter return | Total return | Forecast rationale |
|---|---|---|---|---|
| Q4 2026 | 151.88 | +1.18% | +1.18% | Third-quarter results reaffirm base virology acceleration as Yeztugo adoption expands. Investors look past transient acquisition accounting, though elevated Treasury yields and caution ahead of late-December anito-cel regulatory decisions temper broad valuation multiple expansion. |
| Q1 2027 | 154.55 | +1.76% | +2.96% | Resolution of key regulatory binaries, including anito-cel and once-weekly oral lenacapavir reviews, supports constructive sentiment. Clean fourth-quarter earnings restore positive reported profitability, confirming resilient cash conversion despite ongoing launch commercialization costs. |
| Q2 2027 | 156.86 | +1.49% | +4.49% | Commercial launch execution for once-weekly prevention demonstrates healthy volume growth across domestic channels. Resilient core treatment sales absorb legacy product attrition, while restrictive monetary policy across global central banks continues capping broader market multiples. |
| Q3 2027 | 159.15 | +1.46% | +6.02% | Mid-year financial disclosures confirm underlying operating margin stability near forty percent. Solid free cash flow generation easily funds continuous quarterly dividend disbursements, though preliminary legislative rhetoric regarding drug price negotiations prompts modest sector hesitation. |
| Q4 2027 | 158.45 | -0.44% | +5.55% | Market models begin discounting upcoming 2028 Medicare negotiated price resets on Biktarvy. Strong quarterly volume gains and initial Livdelzi contributions cushion sentiment, but valuation multiple compression moderates overall equity performance into year-end. |
| Q1 2028 | 160.32 | +1.18% | +6.80% | Initial implementation of negotiated Medicare pricing introduces visible gross-to-net discount pressure across exposed domestic channels. However, accelerating global Yeztugo sales and clean full-year 2027 operating cash flow demonstrate durable franchise defense. |
| Q2 2028 | 163.17 | +1.78% | +8.70% | Encouraging Phase 3 data for anito-cel in earlier multiple myeloma settings validates pipeline diversification. Surging prevention adoption offsets government pricing concessions, allowing operational cash flows to resume balance-sheet de-leveraging. |
| Q3 2028 | 164.87 | +1.04% | +9.83% | Late-stage clinical trial progression for once-yearly injectable lenacapavir enhances long-term terminal value visibility. Operating margins remain resilient as manufacturing efficiencies take hold, easily absorbing commercial overhead and sustaining steady equity accumulation. |
| Q4 2028 | 166.75 | +1.14% | +11.08% | Robust second-half cash conversion and disciplined capital allocation support another dividend increase alongside selective share repurchases. International commercial expansion for Yeztugo accelerates, reinforcing defensive institutional demand despite volatile broader equity trading. |
| Q1 2029 | 169.70 | +1.77% | +13.05% | Full-year 2028 financial reporting demonstrates that non-viral specialty products contribute expanding profit shares. Virology cash flows remain resilient against statutory pricing adjustments, supporting modest per-share earnings growth and steady valuation recovery. |
| Q2 2029 | 172.67 | +1.75% | +15.03% | Commercial rollout of next-generation combination therapies preserves high HIV market share against generic threats in older classes. Free cash flow margins remain elite near thirty percent, underwriting opportunistic buybacks across consolidating markets. |
| Q3 2029 | 174.39 | +1.00% | +16.18% | Solid oncology contributions from Trodelvy and advancing antibody-drug conjugate platforms offset routine volume decay in mature antiviral lines. Earnings compound predictably, though approaching loss-of-exclusivity horizons for legacy assets keeps valuation multiples tethered. |
| Q4 2029 | 177.41 | +1.73% | +18.19% | Anticipation of regulatory filings for once-yearly prevention regimens reinforces terminal confidence in virology leadership. High operating cash flow allows management to rebuild liquid reserves while retiring maturing corporate notes into year-end. |
| Q1 2030 | 179.42 | +1.13% | +19.52% | Full-year 2029 results confirm sustainable normalized free cash flow exceeding twelve billion dollars. Strong cash conversion and consistent shareholder distributions provide robust downside insulation as broader macroeconomic growth displays late-cycle cooling. |
| Q2 2030 | 181.00 | +0.88% | +20.58% | Global adoption of long-acting lenacapavir formulations reaches mature scale, successfully migrating patients off aging single-tablet regimens. Oncology revenues expand toward targeted run-rates, defending group operating profitability against persistent government reimbursement friction. |
| Q3 2030 | 183.66 | +1.47% | +22.35% | Terminal multiple discounting emerges as analysts evaluate patent settlement timelines for core therapies entering the five-year forecast horizon. High owner earnings yield and disciplined share retirements fully cushion equity prices against valuation contraction. |
| Q4 2030 | 185.64 | +1.08% | +23.67% | Year-end financial results highlight durable multi-therapeutic diversification spanning virology, liver disease, and hematology. Robust balance-sheet liquidity and conservative interest coverage support consistent per-share compounding despite mature industry valuation multiples. |
| Q1 2031 | 187.70 | +1.11% | +25.04% | Reporting of 2030 annual performance validates unencumbered cash generation and another progressive dividend hike. Stable prescription retention across commercial payer books demonstrates the enduring clinical stickiness of the underlying antiviral ecosystem. |
| Q2 2031 | 189.03 | +0.71% | +25.93% | International market penetration and pipeline milestone execution sustain predictable mid-single-digit top-line growth. Easing macroeconomic capital costs provides mild valuation support, balancing terminal multiple compression as generic settlement deadlines edge perceptibly closer. |
| Q3 2031 | 190.77 | +0.92% | +27.09% | The five-year strategic horizon concludes with the core franchise successfully bridged onto next-generation long-acting regimens. Total shareholder returns reflect steady cash compounding and capital return delivery rather than speculative multiple re-rating. |
The fundamental investment case rests on the economic transition from daily antiretroviral treatment to an ultra-long-acting capsid inhibitor platform. Core virology generates over twelve billion dollars in recurring annual cash flow, funding substantial shareholder distributions and pipeline absorption. However, equity valuation sensitivity centers on the impending Inflation Reduction Act price negotiation for bictegravir starting in 2028 alongside outer-year patent expirationspatent expirationsThe end of patent protection, after which competitors may be able to offer equivalent or similar products.View full glossary entry. While the market excessively discounted headline accounting losses stemming from acquired research charges, durable capital appreciationcapital appreciationThe increase in the market value of an asset over a specific investment horizon.View full glossary entry requires commercial prevention expansion and disciplined business development execution to outpace legislated reimbursement erosion across government channels.
Key insights
- Commercial conversion toward twice-yearly prevention expands the total addressable prophylaxis market rather than merely cannibalizing existing daily oral regimens across commercial books.
- Accounting charges from acquired in-process research mask underlying forty-percent operating marginsoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry, yet external pipeline acquisitions consume genuine balance-sheet liquidity and elevate integration risks.
- Restrictive benchmark interest rates elevate equity hurdle rates, dictating that total shareholder returns depend upon cash compounding rather than terminal multipleterminal multipleValuation metric used to estimate the value of a company beyond the explicit forecast period.View full glossary entry expansion.
The company functions like a profitable tollbooth for vital antiviral treatments, producing massive yearly cash that safely supports regular shareholder dividends. While recent multi-billion accounting write-offs for drug purchases created scary headlines, the underlying sales engine actually accelerated. The primary challenge ahead is government price negotiations on top-selling therapies, meaning sustained financial growth depends on successfully launching convenient new preventive medicines.
Key insights
- Twice-yearly preventive treatments attract new patients who struggle with taking daily prescription pills on strict schedules.
- Huge paper losses from biotechnology acquisitions hide strong operating profits but tie up real cash reserves.
- Government pricing pressure on mature medications will limit valuation expansion, requiring organic earnings growth to deliver returns.
Deep Dive
Prevailing market sentiment anchors on Gilead's recent stock surge, treating flawless clinical efficacy for lenacapavir in prevention as guaranteed long-term growth. Meanwhile, generalist commentary remains unsettled by the headline second-quarter acquisition write-off, assuming upcoming Medicare price negotiations and looming patent horizons will inevitably impair earnings durability. Pricing models largely dismiss acquisition charges as one-off noise while treating terminal cash flows as static annuities.
Paywalled preview begins: Deep Dive: detailed analysis
From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Opinions—and what could close the gap?
Market Narrative
What does the market currently expect? Prevailing market sentiment anchors on Gilead's recent stock surge, treating flawless clinical efficacy for lenacapavir in prevention as guaranteed long-term growth. Meanwhile, generalist commentary remains unsettled by the headline second-quarter acquisition write-off, assuming upcoming Medicare price negotiations and looming patent horizons will inevitably impair earnings durability. Pricing models largely dismiss acquisition charges as one-off noise while treating terminal cash flows as static annuities.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The reports establish that the crowd underestimates underlying cash durability while overestimating near-term multiple expansionmultiple expansionAn increase in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry. The analytical edge centers on recognizing that the ten-billion-dollar GAAP loss was an accounting expensing of upfront acquisition research, not operating cash depletion; trailing free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry exceeds thirteen billion dollars. However, the crowd mistakenly treats twice-yearly prevention as an instant offset to 2028 Medicare price cuts on Biktarvy. True edge lies in modeling steady per-share cash compounding rather than speculative valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry re-rating.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst is the regulatory review window spanning the late December 2026 anito-cel decision and the February 2027 PDUFA action for once-weekly oral lenacapavir. Tangible approval data, accompanied by fourth-quarter disclosures restoring positive GAAP earnings and quantifying paid commercial prescription adoption for Yeztugo, will compel institutional analysts to replace headline accounting skepticism with updated cash flow models reflecting sustainable core franchise compounding.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Balanced
- Volatility
- Moderate
- Cycle position
- Momentum
While reports broadly agree on moderate market volatility, views diverge sharply regarding cycle positioning. Some perspectives diagnose euphoric overshoot after the stock's run to recent highs, whereas others observe early momentum supported by unencumbered cash generation.
Macro Regime Fit
Does the current market environment support the thesis? The prevailing macroeconomic regimemacroeconomic regimeThe prevailing set of economic conditions including interest rates and inflation that influence asset pricing.View full glossary entry of restrictive interest rates and elevated sovereign bond yields presents a mixed setup. Inelastic biological demand for essential antivirals and robust free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry insulate operational earnings from economic deceleration, but benchmark yields near five percent elevate capital hurdle rates, capping equity valuation multiple expansionvaluation multiple expansionAn increase in valuation ratios such as P/E or EV/EBITDA, often driven by stronger growth or lower perceived risk.View full glossary entry.
Advisor Disagreement
What do our AI Advisors disagree about most? The sharpest analytical disagreement centers on terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry and capital allocationcapital allocationThe decision process for directing capital among operations, investment, acquisitions, debt repayment, dividends, and share repurchases.View full glossary entry efficacy. Bullish frameworks view recent multi-billion-dollar acquisition charges as benign accounting artifacts that secured high-growth oncology assets ahead of lenacapavir's commercial ascendancy. Conversely, skeptical frameworks argue that management repeatedly incinerates surplus virology cash on low-return external pipelines while ignoring inevitable 2028 Medicare price cuts and patent cliffs. Resolving this tension requires observing whether twice-yearly prevention adoption and anito-cel commercial revenues generate genuine operating marginoperating marginsOperating profit as a percentage of revenue after operating expenses, before interest and taxes.View full glossary entry expansion before statutory pricing discounts materialize.
Base-Case Forces
Event Risk ScoreVery Low16/100Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Lenacapavir long-acting prevention commercial hegemony | Innovation And Product | +22% | +26% | Twice-yearly injectable lenacapavir transforms HIV prophylaxis by eliminating daily oral pill adherence friction following stellar efficacy in pivotal PURPOSE trials. Rapid commercial adoption expands the addressable prevention cohort into high-margin recurring territory. This clinical breakthrough establishes durable pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and long-term cash generation extending well beyond legacy tenofovir formulations. |
| Biktarvy cash engine patent settlement runway | Competitive Positioning | +15% | +18% | Biktarvy retains domestic treatment dominance, commanding nearly half the HIV patient base with exceptional resistance barriers and high switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry. Established legal settlements defer full generic entry until the mid-2030s. This unyielding commercial annuity delivers massive baseline cash flow that self-funds clinical pipeline development and corporate capital returnscapital returnsDistributions of capital to investors, commonly through dividends or share repurchases.View full glossary entry. |
| High-conversion free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry owner compounding | Capital Allocation | +11% | +10% | Minimal maintenance capital expendituremaintenance capexCapital spending required to keep existing assets operating at their current capacity.View full glossary entry below two percent of revenue allows underlying operations to convert over twelve billion dollars into annual normalized free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry. This prolific cash generation supports steady dividend growth and opportunistic share repurchases, providing an enduring equity valuation floorvaluation floorA price or valuation level believed to have durable support from cash flows, assets, policy, or demand.View full glossary entry and reliable per-share compounding through macroeconomic cycles. |
| Oncology and liver specialty franchise scaling | Sector And Industry | +10% | +12% | Trodelvy label expansion into first-line metastatic breast cancer alongside commercial launches of Livdelzi in primary biliary cholangitis establishes meaningful non-viral diversification. These high-margin specialty therapies leverage existing commercial infrastructure to accelerate operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry, progressively buffering terminal cash flows against eventual loss-of-exclusivity transitions in mature antivirals. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Medicare drug price negotiation margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry | Regulatory | -13% | -15% | Mandatory Medicare Part D price negotiations under the Inflation Reduction Act target top-selling blockbusters, with statutory maximum fair prices for Biktarvy scheduled for 2028 implementation. Enforced discounts and expanding rebate liabilities compress gross-to-net realizations on substantial domestic volume, imposing a permanent structural drag on core virology profit marginsprofit marginsProfit margins measure the share of revenue retained as profit after covering specified costs, expressed as a percentage.View full glossary entry. |
| Impending mid-decade virology patent cliffpatent cliffA period when important patents expire and revenue may fall rapidly because generic or biosimilar competition enters.View full glossary entry discounting | Competitive Positioning | -11% | -8.0% | Financial models progressively discount terminal valuationterminal valuationTerminal valuation is the estimated value of an asset or business beyond the explicit forecast period in a discounted cash flow model.View full glossary entry multiples as loss-of-exclusivity horizons for legacy antiretroviral components approach during the 2030s. While lifecycle migration strategies aim to transition patients to newer combinations, the sheer revenue magnitude of exposed franchises creates persistent multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry that caps equity appreciation despite solid near-term cash generation. |
| Aggressive external pipeline acquisition cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry | Capital Allocation | -9.0% | -10% | Deploying over thirteen billion dollars into external clinical acquisitions creates acute headline accounting losses through acquired research expensing while depleting liquid reserves. Slower commercialization payback, trial attrition, or integration bottlenecks across acquired cell therapy and antibody-drug conjugate assets threaten return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry and constrain near-term share repurchase flexibility. |
| Elevated cost of capitalcost of capitalCost of capital is the required return investors demand to fund a business, project, or asset, reflecting risk and financing mix.View full glossary entry valuation headwind | Macroeconomic And Macrofinancial | -8.0% | -4.0% | The higher-for-longer interest rate environment with sovereign Treasury yields hovering near five percent increases corporate hurdle rates and widens equity discount rates. High risk-free yieldsrisk free yieldsYields on instruments treated as having negligible default risk for a given currency and maturity.View full glossary entry diminish the relative yield appeal of defensive pharmaceutical dividends, compressing institutional price-to-earnings multiples and demanding that shareholder returns rely strictly on fundamental earnings growth. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Accelerated generic Biktarvy patent litigation breach | 24% | -26% | An unexpected federal court ruling invalidating bictegravir formulation patents prior to established settlement horizons would expose the core fourteen-billion-dollar franchise to premature generic erosiongeneric erosionThe loss of market share and revenue as patents expire and cheaper generic alternatives enter the market.View full glossary entry. Wiping out billions in high-margin operating cash flowoperating cash flowCash generated or consumed by a company's core business operations.View full glossary entry before next-generation regimens fully migrate patients would force immediate dividend freezes, credit rating pressure, and severe institutional equity liquidation. |
| Catastrophic acquired oncology pipelineoncology pipelineOncology pipeline refers to the portfolio of cancer-related drug candidates, programs, or studies progressing through research and development stages.View full glossary entry clinical write-downs | 26% | -20% | Confirmatory Phase 3 trial failures or severe toxicities across newly acquired antibody-drug conjugates or cell therapies by 2028 would dismantle non-HIV diversification. Significant clinical setbacks would mandate multi-billion-dollar intangible impairments, permanently destroying invested capital. Disillusioned investors would enforce a steep conglomerate discountconglomerate discountThe tendency for diversified companies to trade at a lower valuation than the sum of their parts.View full glossary entry, contracting forward price-to-earnings multiples to depressed historical troughs. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Why plausible / what changes |
|---|---|---|---|
| Once-yearly lenacapavir formulation regulatory triumph | 35% | +26% | Pivotal Phase 3 PURPOSE 365 trial readouts validating once-yearly intramuscular lenacapavir would revolutionize preventive healthcare by late 2028. Perfect viral protection combined with annual dosing would completely monopolize global prophylaxis and eliminate adherence dropouts. Peak sales could surpass seven billion dollars, driving substantial upward revisions to long-term earnings and expanding valuation multiples. |
| Anito-cel frontline multiple myeloma dominance | 32% | +20% | Pivotal trial data establishing superior complete response durability and zero delayed neurotoxicity for anito-cel could secure accelerated approval in second-line or frontline multiple myeloma by 2028. Displacing incumbent CAR-T therapies would transform cell therapy into a four-billion-dollar oncology cornerstone, vindicating recent acquisition capital deployment and driving significant institutional multiple re-rating. |
Company Financial Analysis
Gilead Sciences Earnings and Financials Analysis by AI
Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
AI Review
Gilead's headline earnings display a dramatic split between accounting figures and operational reality. For the second quarter of 2026, the company reported an eye-catching net loss of over ten billion dollars, yet this paper deficit was driven almost entirely by one-time charges for acquired research. In stark contrast, underlying business performance remained exceptionally strong. Base product revenue climbed ten percent year-over-year, propelled by twelve percent expansion in core HIV medicines and surging prevention demand. Trailing free cash flow exceeded thirteen billion dollars, demonstrating that the underlying cash spigot continues generating robust organic profits.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 29.4B | USD 8.5B | USD 9.5B |
| 2024 | USD 28.8B | USD 480M | USD 10.3B |
| 2023 | USD 27.1B | USD 5.7B | USD 7.4B |
| 2022 | USD 27.3B | USD 4.6B | USD 8.3B |
| 2021 | USD 27.3B | USD 6.2B | USD 10.8B |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 18.1x | TTM | Native | USD / USD |
| 2024 | >100x | TTM | Native | USD / USD |
| 2023 | 18.0x | TTM | Native | USD / USD |
| 2022 | 23.6x | Annual | Native | USD / USD |
| 2021 | 14.7x | Annual | Native | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
AI Review
Gilead commands extraordinary pricing power that keeps underlying profitability among the highest in global healthcare. Gross profit margins consistently hover near seventy-nine percent, sustained by monopolistic antiviral treatments and low manufacturing costs for core tablets. While reported operating margins experienced a temporary paper collapse due to mid-2026 acquisition write-offs, underlying non-GAAP operating margins remain formidable near forty-nine percent. Looking ahead, statutory Medicare price negotiation starting in 2028 will compress net realizations, but rapid adoption of premium preventive formulations should help preserve consolidated operating profitability above forty percent.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 11.7B | 39.7% | 28.9% |
| 2024 | USD 1.7B | 5.8% | 1.7% |
| 2023 | USD 7.6B | 28.0% | 20.9% |
| 2022 | USD 7.3B | 26.9% | 16.8% |
| 2021 | USD 9.9B | 36.3% | 22.8% |
Balance sheet and leverage
AI Review
Gilead's balance sheet reflects substantial financial resilience tempered by recent acquisition spending. Liquid cash reserves contracted to approximately three billion dollars by mid-2026 after funding multi-billion-dollar upfront purchases. Gross debt stands near twenty-six billion dollars, yet debt obligations remain comfortably staggered across future years. The true anchor of balance-sheet safety is powerful cash conversion. Generating over twelve billion dollars in annual operating cash flow gives the company more than ten times interest coverage. This dependable cash generation allows management to comfortably service debt and support shareholder dividends without facing solvency risks.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 24.9B | USD 9.6B | USD 17.4B net debt | 1.55x |
| 2024 | USD 26.7B | USD 11.6B | USD 16.7B net debt | 1.60x |
| 2023 | USD 25B | USD 7.3B | USD 18.9B net debt | 1.43x |
| 2022 | USD 25.2B | USD 6.4B | USD 19.8B net debt | 1.29x |
| 2021 | USD 26.7B | USD 6.5B | USD 21.4B net debt | 1.27x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
AI Review
Management maintains an extraordinarily capital-efficient physical footprint, spending less than two percent of total revenue on property and equipment. Producing small-molecule pills and biologic therapies requires minimal heavy industrial machinery, freeing up operational cash for intellectual property reinvestment. However, true investment intensity happens through external dealmaking. Management deployed over eleven billion dollars in cash during early 2026 to purchase biotechnology pipelines spanning cellular therapy and oncology. While physical capital needs remain light, commercial success now hinges upon turning these costly acquired scientific programs into profitable approved drugs.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 563M | USD 5.8B |
| 2024 | USD 523M | USD 5.9B |
| 2023 | USD 585M | USD 5.7B |
| 2022 | USD 728M | USD 5B |
| 2021 | USD 579M | USD 4.6B |
Quarterly Forecast Scenarios
Gilead Sciences Averaged Consensus Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Quarter | Bear case (USD) | Base case (USD) | Bull case (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $144.11 | $151.29 | $156.11 | $750.26 | |
| $139.78 | $153.92 | $160.80 | $736.44 | |
| $132.79 | $155.75 | $167.23 | $743.40 | |
| $135.45 | $157.88 | $172.25 | $755.15 | |
| $130.03 | $157.43 | $175.69 | $776.22 | |
| $126.13 | $159.54 | $180.96 | $787.13 | |
| $127.39 | $162.29 | $186.39 | $802.83 | |
| $122.30 | $163.72 | $190.12 | $812.05 | |
| $119.85 | $165.67 | $195.82 | $839.18 | |
| $116.25 | $168.19 | $199.74 | $850.50 | |
| $118.58 | $171.11 | $205.73 | $872.39 | |
| $113.84 | $172.44 | $207.79 | $885.51 | |
| $111.56 | $175.48 | $214.02 | $909.56 | |
| $108.21 | $177.30 | $220.44 | $916.13 | |
| $109.30 | $179.32 | $224.85 | $936.51 | |
| $106.02 | $181.61 | $224.92 | $947.34 | |
| $103.90 | $183.57 | $229.42 | $969.59 | |
| $104.93 | $185.90 | $236.23 | $979.99 | |
| $102.84 | $187.41 | $240.95 | $999.60 | |
| $103.86 | $189.44 | $245.84 | $1,012 |
Behind the synthesis
How each opinion shapes the consensus
The evidence across reports establishes a consistent fundamental pattern: headline GAAP net losses in mid-2026 reflect an accounting charge for acquired research rather than operational cash deterioration, with underlying base revenues expanding ten percent and generating over twelve billion dollars in recurring free cash flow. Weighting prioritizes reports grounded in primary SEC filings, verified patent settlement schedules extending Biktarvy exclusivity to 2036, and CMS statutory pricing timelines. Lower weights are assigned to extreme contrarian cases projecting immediate collapse or unconstrained multiple expansion. While the bear case rightly highlights that acquired pipelines deplete liquidity and Medicare price negotiations will compress domestic margins by 2028, it overlooks proven patent duration and rapid twice-yearly prevention adoption. Conversely, peak-multiple bull cases disregard competitive five-percent Treasury yields. The relative weights reflect balanced per-share cash compounding, favoring rigorously evidenced analyses over speculative narratives.
Universal Investor AI
The Polymath
Opus 5Demonstrating premier evidentiary rigor through primary SEC 10-Q citations, FDA approval milestones, and White House pricing pacts, this analysis delivers superior causal clarity. It meticulously dissects the acquired research expensing while modeling realistic long-term compounding across virology and oncology, justifying the highest relative weight in the consensus path.
Universal Investor AI
The Polymath
GPT-6 AstraAnchored in verified primary SEC disclosures and official CMS regulatory determinations, this report provides exceptional evidentiary quality. It rigorously reconciles reported accounting losses with normalized cash flow while incorporating realistic margin friction from federal pricing negotiations and cost of capital benchmarks, justifying a leading weight in the overall synthesis.
Sherlock Holmes AI
The Whistleblower
Gemini 3.8 FlashThis report provides outstanding forensic examination of balance-sheet liquidity, debt maturity schedules, and non-GAAP margin reconciliation. It accurately models the timing of oral lenacapavir catalysts alongside realistic regulatory price headwinds. Its high evidentiary grounding and balanced long-term return profile warrant a substantial conviction weight.
Universal Investor AI
The Polymath
Gemini 3.8 FlashPresenting thorough analysis of Biktarvy generic patent settlements extending to 2036 alongside verified Trodelvy first-line label expansions, this report establishes high evidentiary quality. It convincingly explains why underlying business acceleration easily absorbs transient accounting charges, warranting a high weight reflecting its balanced, evidence-backed operational optimism.
Ray Dalio AI
The Strategist
Gemini 3.8 FlashThis perspective excels in contextualizing biopharmaceutical cash generation within restrictive macroeconomic tightening and sovereign yield competition. It recognizes that equity returns must stem from organic operational earnings compounding rather than terminal multiple expansion. Its sound macro transmission mechanisms justify an above-average weight despite lighter company-specific pipeline granular detail.
Universal Investor AI
The Polymath
Gemini 3.8 FlashThis analysis demonstrates solid causal consistency, recognizing that trailing accounting losses reflect one-off transaction charges rather than operational decay. It correctly balances lenacapavir launch execution against upcoming Medicare price negotiations. However, the lack of granular primary filing receipts justifies a measured weight relative to more thoroughly documented peers.
Niccolo Machiavelli AI
The Insider
Gemini 3.8 FlashThis perspective offers valuable insights into global access voluntary licensing and diplomatic insulation from populist price controls. It correctly identifies how upfront M&A expensing distorts headline metrics while core revenues expand. The weight reflects this strong political and institutional analysis, balanced against somewhat optimistic oncology commercial assumptions.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashOffering a disciplined owner-earnings framework, this analysis properly emphasizes capital-light economics and high cash conversion. It soundly identifies valuation risks at current trading multiples while acknowledging durable competitive moats. A solid weight is warranted, though slight repetition of generalized value tropes keeps it below primary filing-grounded reports.
Michael Burry AI
The Vulture
Gemini 3.8 FlashThis report provides a credible discipline check on valuation, highlighting how high benchmark Treasury yields compress pharmaceutical price-to-earnings multiples. It accurately models statutory pricing drag and acquisition integration costs, though it somewhat underestimates the margin durability and total addressable market expansion delivered by twice-yearly injectable prevention regimens.
Elon Musk AI
The Visionary
Gemini 3.8 FlashThis analysis astutely diagnoses management's persistent tendency to deplete operational cash through speculative oncology acquisitions. It balances this friction against lenacapavir's biological moat. While offering sharp causal mechanisms, its somewhat cynical narrative on corporate capital allocation is tempered by evidence of disciplined underlying free cash flow generation.
Warren Buffett AI
The Value Seeker
Gemini 3.8 FlashThis assessment provides a healthy skepticism regarding margin of safety and liquidity depletion following aggressive M&A disbursements. However, its conservative assumption of owner earnings fails to fully credit rapid Yeztugo commercial adoption and proven legal patent insulation, justifying a modest weight that preserves its prudent cautionary signals.
J.P. Morgan AI
The Titan
Gemini 3.8 FlashThis report provides strong enthusiasm for Yeztugo but incorporates overly aggressive multiple expansion assumptions that disregard the prevailing high interest-rate regime. While correctly identifying core virology durability, its terminal enterprise valuation expansion exceeds prudent risk boundaries. A moderate weight preserves its commercial insight without overcommitting to its exuberant trajectory.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashWhile providing a useful contrarian warning regarding Biktarvy patent expiry and historical oncology capital destruction, this report overstates structural operational decay. Projecting severe persistent negative equity returns ignores thirteen billion dollars in annual free cash flow and proven generic settlement protection extending into the 2030s, warranting a restricted weight.
Superintelligence AI
The Anthropologist
Gemini 3.8 FlashWhile offering detailed pipeline progression scenarios across oncology and long-acting prevention, this report assumes an overly optimistic multiple re-rating and rapid earnings acceleration. It underestimates structural drag from statutory Medicare price negotiations and elevated cost of capital, warranting a low weight to avoid skewing the consensus trajectory upward.
Research Provenance
References & Context
This Gilead Sciences consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
- Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.
Independent AI Advisor panel
- AI Advisors
- 14
- AI Researchers
- 11
- AI Thinkers
- 3
Sources retained from AI Researcher searches
Asset-specific · Researcher webShowing the top 15 of 125 deduplicated sources retained for this batch.
- 01CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs | CMScms.gov
- 02gild-20260630sec.gov
- 03GILEAD SCIENCES, INC. - Form 10-Q - FY2026sec.gov
- 04GILEAD SCIENCES, INC. - Form DEF 14A - FY2026sec.gov
- 05Lakefront Biotherapeutics NV - Form 6-K - FY2026sec.gov
- 06Fact Sheet: President Donald J. Trump Announces Deal with Nine Additional Pharmaceutical Manufacturers to Lower Drug Prices for Americans – The White Housewhitehouse.gov
- 07Savings from Most-Favored-Nation Drug Pricing Policy – The White Housewhitehouse.gov
- 08Gilead Sciences, Inc. - Gilead Sciences Announces Second Quarter 2026 Financial Resultsinvestors.gilead.com
- 09Trump Strikes 9 New Pricing Agreements as Drugmakers Navigate Tariff, Regulatory Pressure | AJMCajmc.com
- 10Gilead raises full-year guidance on 8% Q2 sales growth, eyes three near-term regulatory approvalsallsci.com
- 11Gilead Wins FDA Nod for Bixlenvo, New HIV Pill | AskTraders.com %asktraders.com
- 12FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientscnbc.com
- 13Drug companies sign "Most Favored Nation" deals, then raise prices anywaydrugdiscoverytrends.com
- 14With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'fiercebiotech.com
- 159 pharma giants reach US drug price deals with Trump administrationfiercepharma.com
And 110 more sources were used and retained in the batch inventory.
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market and World-Events Context Through September 20
Download Archived SnapshotCoverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20
January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.
Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| Renewed monetary tightening amid persistent inflation | 2026-01-30 | ACTIVE POLICY REGIME |
| Iran/Hormuz conflict and wider energy-security disruption | 2026-02-28 | ONGOING |
| Tariff legal reset and strategic supply restrictions | 2026-02-20 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
9 fieldsdepreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields
Balance sheet
12 fieldscash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields
Cash flow
5 fieldscapitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field
annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).
End of the paywalled preview
The excerpt from Deep Dive: detailed analysis to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.
Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.
Additional with full access
Individual AI Advisor reports
- Investment theses
- Bull and bear scenarios and alpha signals
- Drivers, headwinds, risks and opportunities
- Quarterly forecast rationale
- Advisor research references and configuration
Additional datasets and interactive tools
- Interactive forecast comparisons
- Available detailed financial statements
- Market history and corporate-action adjustments
- Eligible historical publication workspaces
Explore complete public research examples
These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.